The long-term corporate and clinical prospects for Tenaya Therapeutics depend entirely on the successful clinical development, regulatory approval, and commercialization of its proprietary gene therapies and small-molecule drugs targeting severe heart failure and genetic cardiomyopathies. Positive clinical data readouts could position the firm as a leader in cardiovascular genetic medicine, whereas clinical setbacks present substantial valuation headwinds.